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ABSTRACT 
BACKGROUND:  Insulin resistance is a critical aspect of the pathophysiology of 
type 2 diabetes mellitus and is also associated with other risk factors for cardiovascular 
disease (eg, dyslipidemia nd hypertension). Accordingly, insulin resistance is a pos- 
sible target for lowering plasma glucose concentration a d preventing diabetic macro- 
angiopathy. Biguanides, such as metformin, and thiazolidinediones (TZDs), such as 
pioglitazone, improve insulin resistance. 
OBJECT IVES:  The aims of this study were to assess the effects of replacing a 
biguanide with a TZD on glycemic ontrol in patients with poorly controlled type 2 
diabetes mellitus, and also to identify the factors affecting interpatient variation in the 
effects of treatment change. 
METHODS:  This was a 12-week, open-label, prospective study in which previ- 
ously prescribed metformin (500 or 750 mg/d) was replaced with pioglitazone (15 or 
30 mg/d) in patients with poorly controlled type 2 diabetes mellitus. Patients with a 
glycosylated hemoglobin (HbAlc) concentration >7% despite treatment with diet, 
exercise, and hypoglycemic agents other than TZDs were eligible for the study. 
Patients who never received TZDs were also eligible for inclusion. Vital signs, meta- 
bolic parameters, and arterial stiffness were assessed at baseline and after 12 weeks of 
treatment with pioglitazone. The primary end point was change in HbAlc concentra- 
tion after replacing metformin with pioglitazone. Tolerability was assessed by medical 
history, physical examination, and laboratory tests (aspartate aminotransferase, alanine 
aminotransferase, and ]'-glutamyl transpeptidase). 
RESULTS:  Twenty-one Japanese patients (15 women, 6 men; mean [SD] age, 
61.8 [8.4] years; body mass index, 25.5 [3.0] kg/m 2) were included in the study. 
HbAI~ concentration was not significantly changed from baseline after 12 weeks of 
pioglitazone treatment (8.0% [0.7%] vs 8.2% [0.7%]). Fasting plasma glucose (FPG) 
concentration also was not significantly changed after the replacement of treatment 
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(156 [27] vs 144 [30] mg/dL). In addition, the resistin concentration did not change 
significantly from baseline after 12 weeks of pioglitazone treatment (6.6 [3.8] vs 
6.4 [3.6] ng/mL). In contrast, significant improvement from baseline was observed in 
triglyceride (TG) concentrations (157 [109] vs 117 [68] mg/dL; P 0.003), high- 
density lipoprotein cholesterol (HDL-C) (55 [12] vs 61 [16] mg/dL; P 0.016), 
remnant-like particle cholesterol (6.6 [6.0] vs 5.3 [3.5] mg/dL; P 0.048), and serum 
adiponectin (8.8 [4.3] vs 23.3 [11.7] lag/mL; P < 0.001). Pulse wave velocity was also 
significantly improved (1730 [361] vs 1622 [339] m/sec; P 0.009). Changes in 
HbAlc were significantly correlated with serum fasting insulin concentration at base- 
line in the patients not receiving insulin preparations (r 0.635, P 0.013). The 
percentage change in serum adiponectin concentration was correlated with the per- 
centage changes in HbAlc and FPG concentrations (HbAl~ , r 0.518, P 0.019; 
FPG, r 0.594, P 0.006). Body weight was significantly increased after treatment 
(62.6 [11.9] vs 65.5 [12.2] kg; P < 0.001). Mild edema was reported in 5 patients. 
One patient discontinued treatment due to an increase in serum creatine kinase 
activity to -6.6 times the upper limit of normal. 
CONCLUSIONS:  Replacement of metformin with pioglitazone did not produce 
significant differences in HbAl~ and FPG concentrations from baseline after 12 weeks 
of treatment in these patients with poorly controlled type 2 diabetes mellitus. How- 
ever, the replacement was effective in a subset of patients whose serum insulin con- 
centrations were high or whose serum adiponectin concentrations were sensitive to TZDs. 
In addition, the replacement was associated with significant improvements in TG, 
HDL-C, serum adiponectin concentration, pulse wave velocity, and body weight 
increase from baseline. (Curt Ther Res C/in Exp. 2008;69:364 377) © 2008 Excerpta 
Medica Inc. 
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INTRODUCTION 
Insulin resistance is a critical aspect in the pathophysiology of type 2 diabetes melli- 
tus i and is also associated with other risk factors for cardiovascular disease (eg, dys- 
lipidemia and hypertension). 2 Accordingly, insulin resistance is a possible target for 
lowering plasma glucose concentration and preventing diabetic macroangiopathy. 
Biguanides, such as metformin, and thiazolidinediones (TZDs), such as pioglita- 
zone, improve insulin resistance. 3 Both drugs are useful for metabolic control in 
patients with type 2 diabetes mellitus. Although the mechanism of action of met- 
formin remains unclear, it is primarily found to reduce hepatic glucose output)  
Adenosine monophosphate~ctivated protein kinase has been proposed as the molecu- 
lar mechanism of action in metformin. 5 In contrast o metformin, TZDs seem to 
promote glucose disposal rather than being responsible for the inhibition of endoge- 
nous glucose production) The TZD troglitazone is a ligand of peroxisome proliferator- 
activated receptor 7 that induces adipocyte differentiation, making adipocytes mall 
and insulin-sensitive. 6 Therefore, there are differences in the mechanisms of action of 
the 2 drugs. 
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The effects of metformin and pioglitazone have been compared in randomized tri- 
als. 7,8 The overall reductions ofglycosylated hemoglobin (HbAlc) concentrations were 
found to be similar in the 2 treatment groups (metformin vs pioglitazone: 1.5% vs 
1.3% 7 and 1.5% vs 1.4%s). However, it remains to be determined whether the 
2 drugs have similar glucose-lowering effects in subsets of patients with type 2 dia- 
betes mellitus because the effect of TZDs is known to vary among individuals. 9,1° In 
the postmarketing surveillance study of Japanese type 2 diabetes mellitus patients 
treated with pioglitazone, the relationship between change in HbAI~ and body mass 
index (BMI) or insulin level was not statistically analyzed, u 
The aims of this study were to compare glucose control, metabolic parameters, and 
risk factors of atherosclerosis before and after replacing metformin with pioglitazone 
in patients with poorly controlled type 2 diabetes mellitus and also to identify the 
factors affecting interpatient variation in the effects of treatment change. 
PAT IENTS AND METHODS 
PAT IENTS 
We recruited patients with type 2 diabetes mellitus from Hokkaido University 
Hospital (Sapporo, Japan) and Iwamizawa Municipal General Hospital (Iwamizawa, 
Japan) who were receiving metformin (500 or 750 mg/d) and who were not optimally 
controlled. These are the dosages that are approved and typically prescribed in Japan 
as described elsewhere. 12,13 
Patients with an HbAlc concentration > 7 % despite treatment with diet, exercise, 
and hypoglycemic agents other than TZDs and who had never received TZDs were 
eligible for the study. Patients with any of the following conditions were excluded: 
heart failure; diabetic nephropathy with proteinuria or increased serum creatinine 
concentration (> 1.0 mg/dL); uncontrolled iabetic retinopathy; liver dysfunction 
(aspartate aminotransferase activity > 100 U/L or alanine aminotransferase [ALT] 
activity > 100 U/L); or pregnancy. 
Patients who met the inclusion criteria and agreed to participate were consecu- 
tively recruited in the study. This study was approved by the Institutional Review 
Board of Hokkaido University Hospital (Sapporo, Japan) and was carried out accord- 
ing to the Declaration of Helsinki. 14 Written informed consent was obtained from all 
participants. There was no compensation for study participation. 
STUDY DES IGN 
This was a 12-week, open-label, prospective study in which previously prescribed 
metformin (500 or 750 mg/d) was replaced with pioglitazone (15 or 30 mg/d) in 
patients with poorly controlled type 2 diabetes mellitus. The patients were instructed 
to replace metformin with pioglitazone (15 mg once daily, after breakfast) on the day 
following study entry. Four weeks after drug replacement, the patients were assessed 
for adverse events (AEs) using medical history, physical examination, and liver func- 
tion tests. If no AEs were observed, the pioglitazone dose was increased to 30 mg once 
daily. Tolerability was checked at weeks 8 and 12. Medication compliance was moni- 
tored by patient report at weeks 8 and 12 as well. Visits that were delayed <2 weeks 
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were permitted. Administration of pioglitazone was continued until week 12. Other 
medications were unchanged uring the study. 
MEASUREMENTS 
BMI was calculated using the following equation: body weight (kg)/height (m2). 
Blood pressure (BP) was measured using a sphygmomanometer with subjects in the 
sitting position by physicians who were not blinded to the study objectives or meth- 
ods. Mean BP was calculated using the following equation: 
diastolic BP + (systolic BP diastolic BP)/3. 
Metabolic parameters were examined at baseline and week 12 to evaluate the ef- 
fects of the drug substitution. Blood sampling was performed in the morning after 
overnight fasting. For measurements of fasting plasma glucose (FPG) and HbA1c con- 
centrations, blood was collected in plastic tubes including NaF and Na 2- 
ethylenediamine tetraacetic acid and centrifuged, and the resultant plasma was used. 
Concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein 
cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), and lipoprotein a 
(Lp(a)) were measured for comparison with lipid profiles and serum adiponectin, and 
resistin concentrations were measured for comparison with serum adipocytokine con- 
centration. Serum used for those measurements were prepared by centrifugation of
blood collected in plastic ubes including no anticoagulant. 
To assess arterial stiffness, brachial-ankle pulse wave velocity (PWV) was measured 
at baseline and week 12 using volume plethysmography (Form PWV/ABI, Colin Co. 
Ltd., Komaki, Japan). The measurements were done by laboratory technicians who
were blinded to the aims of the study. A mean of right and left measurements was used 
for the analysis. 
OUTCOME MEASUREMENTS 
The primary variable was change in HbAic concentration. Secondary parameters 
included FPG concentration, fasting plasma lipid concentrations, adipocytokines, BP, 
PWV, and body weight. 
The relationships between changes in HbAic concentration and secondary parame- 
ters (FPG concentration, fasting plasma lipid concentrations, adipocytokines, BP, 
PWV, and body weight) were also tested. 
STAT IST ICAL  ANALYS IS  
The data analyses were performed as intent-to-treat. Measured parameters at0 and 
12 weeks were compared using the paired t test. Sample size was based on the primary 
end point (change in HbAic concentration after 12 weeks of treatment with pioglita- 
zone). Based on the findings of a previous study, 8 when the SD of differences in HbAic 
changes was assumed to be 1.0, for a 2-sided paired t test to detect a 0.7% difference 
in HbAic concentration with 5% significance and 80% power, a sample size of 
> 19 patients was needed. The changes in HbAic concentration a d secondary parame- 
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ters measured at baseline were analyzed to obtain Pearson's correlation coefficients. 
The relationship between the percentage changes in HbAl~ or FPG concentrations 
and those of the secondary measured parameters were similarly analyzed. Values were 
presented as mean (SD). Differences were considered significant at P < 0.05. 
RESULTS 
PAT IENTS 
Twenty-one Japanese patients (15 women, 6 men; mean [SD] age, 61.8 [8.4] years) 
were included in the study. Twenty patients were receiving metformin 750 rag/d, and 
1 patient was receiving metformin 500 mg/d. Baseline characteristics, including the 
drugs used at baseline, are shown in Table I. Mean BMI was 25.5 (3.0) kg/m 2, 
which is above the cutoff value for a diagnosis of obesity in Japan. 15 At baseline, 
11 patients were receiving treatment for hypertension, and 12 were receiving treat- 
ment for dyslipidemia. 
Vital signs and laboratory findings at baseline and after 12 weeks of pioglitazone 
treatment are shown in Table II. The baseline blood glucose concentration was unsatis- 
factory, which could be accounted for by the inclusion criteria (HbAl~ , 8.0% [0.7%]; 
FPG, 156 [27] mg/dL). At baseline, systolic BP was 135 (19) mm Hg, diastolic BP 
was 78 (12) mm Hg, and mean BP was 97 (12) mm Hg. TG and RLP-C concentra- 
tions were elevated (TG, 157 [109] mg/dL; RLP-C, 6.6 [6.0] mg/dL). These findings 
suggested impaired lipoprotein metabolism. 
Serum insulin concentration was determined in the 14 patients among those who 
did not receive insulin therapy (7.6 [6.3] laU/mL). Two patients had RLP-C concen- 
tration values below the measurable imit (2.0 mg/dL) after 12 weeks of treatment and 
1 patient had a Lp(a) concentration value below the measurable limit (1.0 mg/dL) 
throughout the study. These values were not included in the analysis. If the minimum 
values within the measurable ranges were applied to the analysis instead of those sub- 
minimal values, the results did not differ. 
One patient did not complete the 12-week study because of an increase in serum 
creatine kinase activity. Of the 20 patients who did complete the study, 1 patient did 
not have a laboratory test at week 8 but continued to receive pioglitazone for the 
12-week treatment period. In 1 patient, an increase in the dose of pioglitazone was 
postponed until week 8 due to edema. 
EFFECTS OF  DRUG REPLACEMENT 
Glycemic control, evaluated using HbAlc concentration, did not significantly 
change from baseline after 12 weeks of treatment (8.0% [0.7%] vs 8.2% [0.7%]) 
(Figure 1A). FPG concentration was also unchanged (156 [27] vs 144 [30] mg/dL) 
(Figure 1B). However, individual differences were found: HbAlc and FPG concentra- 
tions decreased in 6 and 11 patients, respectively. 
With regard to lipid metabolism, TC concentration did not significantly change 
from baseline after 12 weeks of treatment (194 [35 ] vs 192 [39] mg/dL). TG concen- 
tration decreased significantly (157 [ 109] vs 117 [68] mg/dL; P 0.003) and HDL-C 
concentration i creased significantly (55 [12] vs 61 [16] mg/dL; P 0.016). RLP-C 
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Table I. Baseline demographic and clinical characteristics 
of the Japanese study patients (N = 21). 
Characteristic Value 
Age, mean (SD), y 61.8 (8.4) 
Sex, no. (%) 
Female 15 (71.4) 
Male 6 (28.6) 
Duration of diabetes, mean (SD), y 10.3 (5.1) 
Body mass index, mean (SD), kg/m 2 25.5 (3.0) 
Drugs taken at baseline, no. 
Antidiabetic drugs, except biguanides 
Sulfonylureas only 7 
Sulfonylureas + c~-GI 6 
Insulin only 2 
Nateglinide + c~-GI 2 
Nateglinide only 1 
Insulin + c~-GI + nateglinide 1 
None 2 
Antihypertensive drugs* 
ARBs 10 
Calcium channel blockers 5 
Diuretics 3 
ACE inhibitors 3 
c~-Blockers 2 
13-Blockers 2 
Lipid-lowering drugs 
Statins 12 
Niacin 0 
c~-GI = c~-glucosidase inhibitor; ARBs = angiotensin II receptor blockers; 
ACE = angiotensin-convert ing enzyme. 
*Some pat ients were receiving >1. 
concentration also decreased significantly (6.6 [6.0] vs 5.3 [3.5] mg/dL; P 0.048). 
However, Lp(a) concentration did not change significantly (15.7 [21.5] vs 18.3 [21.4] 
mg/dL). Serum adiponectin concentration i creased in all patients (8.8 [4.3] vs 
23.3 [11.7] pg/mL; P < 0.001), whereas the resistin concentration did not change 
significantly from baseline after 12 weeks of pioglitazone treatment (6.6 [3.8] vs 
6.4 [3.6] ng/mL). PWV decreased significantly (1730 [361] vs 1622 [339] m/sec; P 
0.009) (Table II). 
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Table II. Vital signs and laboratory findings at baseline and after replacing metformin 
with pioglitazone for 12 weeks in Japanese patients with poorly controlled 
type 2 diabetes mellitus. Data are mean (SD). 
Variable Baseline Week 12 P 
Mean blood pressure, mm Hg 97 (12) 93 (13) 0.150 
Body weight, kg 62.6 (11.9) 65.5 (12.2) <0.001 
Fasting plasma glucose, mg/dL 156 (27) 144 (30) 0.139 
Glycosylated hemoglobin, % 8.0 (0.7) 8.2 (0.7) 0.450 
Total cholesterol, mg/dL 194 (35) 192 (39) 0.955 
Triglycerides, mg/dL 157 (109) 117 (68) 0.003 
HDL-C, mg/dL 55 (12) 61 (16) 0.016 
RLP-C, mg/dL 6.6 (6.0) 5.3 (3.5) 0.048 
Lipoprotein(a), mg/dL 15.7 (21.5) 18.3 (21.4) 0.100 
Insulin, pU/mL 7.6 (6.3) 6.6 (3.9) 0.119 
Adiponectin, pg/mL 8.8 (4.3) 23.3 (11.7) <0.001 
Resistin, ng/mL 6.6 (3.8) 6.4 (3.6) 0.590 
Pulse wave velocity, m/sec 1730 (361) 1622 (339) 0.009 
Aspartate aminotransferase, U/L 25 (10) 23 (8) 0.172 
Alanine aminotransferase, U/L 29 (14) 22 (9) 0.001 
HDL-C = high-density lipoprotein cholesterol; RLP-C = remnant-like particle cholesterol. 
RELAT IONSHIP  BETWEEN GLYCEMIC  CONTROL AND ADIPONECTIN  
CONCENTRATION 
The change in HbA1c concentration was significantly correlated with serum fasting 
insulin concentration at baseline in patients not receiving insulin (r 0.635, P 
0.013) (Table III). In addition, the percentages of the changes in HbA1c and FPG 
concentrations were correlated with the percentage of the change in adiponectin 
(HbA1c, r 0.518, P 0.019; FPG, r 0.594, P 0.006) (Figure 2). 
TOLERABIL ITY  AND SAFETY  PROFILE  
Body weight increased significantly (62.6 [11.9] vs 65.5 [12.2] kg; P < 0.001) 
after 12 weeks of pioglitazone treatment (Table II). Mild edema was reported in 
5 patients, while no patient experienced hepatotoxicity. ALT activity decreased 
(29 [14] vs 22 [9] U/L; P 0.001). At week 8, 1 patient discontinued the study due 
to an increase in serum creatine kinase activity, which was -6.6 times the upper limit 
of normal, although there were no associated symptoms. After discontinuing pioglita- 
zone treatment, he serum creatine kinase activity normalized (213 U/L at baseline 
vs 1192 U/L at week 8 vs 94 U/L at week 12). 
DISCUSSION 
In this study, we assessed the effects of replacing metformin with pioglitazone in pa- 
tients with poorly controlled type 2 diabetes mellitus. HbAlc concentration was 
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Figure 1. Changes in (A) glycosylated hemoglobin (HbAlc) and (B) fasting plasma glucose 
(FPG) concentrations 12 weeks after replacing metformin with pioglitazone in 
Japanese patients with poorly controlled type 2 diabetes mellitus. 
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Table III. Correlation analysis of the association between a change in glycosylated 
hemoglobin concentration and baseline vital signs and laboratory findings. 
Variable Correlation Coefficient P 
Mean blood pressure, mm Hg 
Body weight, kg 
Fasting plasma glucose, g/dL 
Glycosylated hemoglobin, % 
Total cholesterol, mg/dL 
Triglycerides, mg/dL 
HDL-C, mg/dL 
RLP-C, mg/dL 
Lipoprotein(a), mg/dL 
Insulin, pU/mL 
Adiponectin, pg/mL 
Resistin, ng/mL 
Pulse wave velocity, m/sec 
Aspartate aminotransferase, U/L 
Alanine aminotransferase, U/L 
0.224 0.349 
-0.214 0.371 
-0.382 0.097 
-0.428 0.059 
0.214 0.370 
0.293 0.213 
-0.075 0.758 
0.285 0.227 
0.071 0.777 
-0.635 0.013 
0.131 0.588 
-0.087 0.718 
0.119 0.623 
-0.221 0.354 
-0.157 0.515 
HDL-C = high-density lipoprotein cholesterol; RLP-C = remnant-like particle cholesterol. 
unchanged 12 weeks after replacement, corresponding with the findings of other ran- 
domized, placebo-controlled studies. 7,8 However, there was a subset group in which 
HbAlc had opposite outcome measures it improved in one group of patients and it 
deteriorated in another group of patients. These findings suggest hat replacing metfor- 
min with pioglitazone is useful for glycemic ontrol in some patients. 
The reduction in HbAlc concentration was significantly correlated with serum fast- 
ing insulin concentration at baseline. This is compatible with the results of an obser- 
vational study in which the glucose-lowering effect of pioglitazone was found to be 
greater in patients with high insulin concentrations. 11 In patients whose insulin con- 
centrations are high, the transition from metformin to pioglitazone therapy may be 
effective. 
After drug replacement, serum adiponectin concentration significantly increased in 
12 weeks. TZDs, including pioglitazone, have been reported to increase serum 
adiponectin concentration, 16 18 whereas no increase in adiponectin concentration 
was found with metformin therapy. 19 The results in this study supported the effect 
of pioglitazone on serum adiponectin concentration. This increase may be favorable 
for the prevention of cardiovascular disease and enhancement of insulin sensitivity. 2°
We found a correlation between the change in plasma glucose concentration and the 
change in serum adiponectin concentration, which suggests that the glucose-lowering 
effect of pioglitazone is likely to be linked to an increased adiponectin concentration. 
This finding supports a previous study 21 that reported the correlation between an 
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Figure 2. Correlation of percentage changes in (A) glycosylated hemoglobin (HbAlc) (r = 
-0 .518,  P = 0.019) and (B) fasting plasma glucose (FPG) concentrations with 
those of serum adiponectin concentrations (r = -0.594,  P = 0.006) 12 weeks 
after replacing metformin with pioglitazone in Japanese patients with poorly 
controlled type 2 diabetes mellitus. 
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increase in plasma adiponectin concentration and improvement in insulin sensitivity 
by pioglitazone valuated with a euglycemic insulin clamp in subjects with uncon- 
trolled type 2 diabetes mellitus who were receiving a stable dose of sulfonylurea. 
Although it has been proposed that TZD ameliorates glucose tolerance via not only 
adiponectin-dependent bu also adiponectin-independent pathways in experiments 
using animal models, 22 adiponectin secretion capacity seems to be a key factor in as- 
sociation with the glucose-lowering eftect of pioglitazone. 
Replacing metformin with pioglitazone was associated with significant changes in 
the lipid profile. Concentrations of TG and HDL-C both improved significantly after 
drug replacement, supporting the findings of a previous randomized, double-blind 
study comparing pioglitazone with metformin in drug-naive patients with type 2 
diabetes mellitus. 8 A significant decrease in RLP-C concentration was also observed 
in the present s udy. Therefore, in cases with such lipid abnormalities, which are often 
seen in obese patients, pioglitazone may be an option for patients poorly controlled on 
metformin. 
We found that PWV was significantly decreased after the transition to pioglitazone 
treatment. This finding is in agreement with that of Satoh et al, 23 a prospective, 
nonplacebo-controlled study in Japanese patients with type 2 diabetes mellitus, who 
reported that pioglitazone improved PWV independent of its antidiabetic effect. Be- 
cause PWV is not only an index of vascular stiffness but also predicts mortality and car- 
diovascular diseases, 24 26 our findings suggested that pioglitazone had favorable ef- 
fects on vascular isk for at least 12 weeks. 
The present study found that pioglitazone increased body weight, as shown previ- 
ously, 27,28 although glycemic control was unchanged. Promotion of pioglitazone 
should be avoided in treating type 2 diabetes mellitus in obese patients. It is well 
known that metformin causes less weight gain and is advantageous in treating obese 
patients with diabetes. 29,3° 
There were no cases of liver toxicity in this study, although 1 patient discontinued 
the study at week 8 due to an increase in serum creatine kinase activity. Serum ALT 
activity decreased rather than increased after drug replacement. This may be because 
steatosis was more improved by pioglitazone 31,32 than metformin, although met- 
formin was also found to have a favorable ftect on fatty liver disease. 33 35 
L IMITAT IONS 
This study had several limitations. A crossover study would have been more appro- 
priate to examine the eftect of drug replacement in each individual. In addition, the 
number of patients was small and no control group was used. Another limitation was 
using patients' reports to establish adherence to treatment and to assess AEs, which 
created recall bias. Although correlations between a change in HbAlc concentration 
and various parameters were tested for exploratory analysis, there was no adjustment 
for multiple comparisons. 
Patients enrolled in this study had been receiving 500 or 750 mg/d of metformin. 
The dosage of 750 mg/d is the maximum recommended for the treatment of diabetes 
in Japan. This dosage is smaller than that used in other countries. ~2,~3 Use of a higher 
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dose of metformin, which is more effective in glycemic control than a lower dose, 36 
may have achieved control in these patients. 
CONCLUSIONS 
Replacement of metformin with pioglitazone did not produce significant differences 
in HbAic and FPG concentrations from baseline after 12 weeks of treatment in these 
patients with poorly controlled type 2 diabetes mellitus. However, the replacement 
was effective in a subset of patients whose serum insulin concentrations were high or 
whose serum adiponectin concentrations were sensitive to TZDs. In addition, the 
replacement was associated with significant improvements in TG, HDL-C, serum adi- 
ponectin concentration, PWV, and body weight increase from baseline. 
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